Article
Hamilton’s Pharma Cope, Part 4: “The Face of Psychedelic Journalistic Ethics” Transcript
In this episode, we continue the conversation about our funding and explore Hamilton Morris’ conspiratorial claims about the company Usona.
Article
In this episode, we continue the conversation about our funding and explore Hamilton Morris’ conspiratorial claims about the company Usona.
Article
In this episode, we continue the conversation about our funding and explore Hamilton Morris’ conspiratorial claims about the company Usona.
Article
In this episode, we examine previous smear campaigns against us related to our reporting on the Church of Psilomethoxin and Martin Ball, as well as false claims about who funds us and why.
Article
In this episode, we respond to Hamilton Morris’ claims that we are DEA informants and that we colluded with the FDA to get Lykos Therapeutics’ MDMA therapy application rejected.
Article
Part 4 of The Psychedelic Syndicate reveals PSFC’s strategy to manufacture spiritual and moral authority through academic capture — even as some members align with far-right ideologies that deepen the very crises psychedelics are meant to heal.
Article
Part 3 of The Psychedelic Syndicate exposes how Silicon Valley’s “move fast and break things” mentality infected psychedelic therapy, creating a culture where leaders rationalized patient harm as unavoidable for progress and ultimately embraced Trump administration officials who promised regulatory
Article
Part 2 of The Psychedelic Syndicate exposes the compromised foundation of PSFC’s influence network — from the abuse scandals that undermined their preferred therapy model, to undisclosed ties with the sole FDA advisory committee member who voted unequivocally for MDMA approval.
Article
Part 1 of The Psychedelic Syndicate reveals how the Psychedelic Science Funders Collaborative (PSFC) — a wealthy network of Silicon Valley elites and Burning Man devotees — systematically captured the psychedelic movement by influencing MAPS, funding its subsidiary Lykos’ MDMA clinical trials, and p
Article
Rather than unpacking the actual causes of Lykos Therapeutics’ disastrous Phase 3 trials and FDA rejection, The New York Times produced a work of fictitious propaganda that prioritizes corporate interests over public health.
Article
In response to The New York Times February 4 article, “How a Leftist Activist Group Helped Torpedo a Psychedelic Therapy,” Psymposia requested corrections to numerous errors and false accusations.
Article
Veterans deserve the highest quality treatment for PTSD. It’s unacceptable and dangerous to use veterans as guinea pigs for a big pharma profit grab without resolving safety and efficacy concerns.
Article
Language used by mainstream media affects the way we think about and respond to sexual violence, and no language is neutral. When journalists repeat the misrepresentations of abusers without qualification, they retraumatize victims and perpetuate ongoing misogynistic views about sexual violence.
Psymposia is a research and media 501(c)(3) nonprofit that offers critical perspectives on drugs, politics, and culture. We rely on audience support to keep our work independent and focused on the public interest. You can sustain Psymposia by becoming a member, which includes exclusive content and perks.